Attach to Form 990 or Form 990-EZ.
See separate instructions.| (i) Name of supported organization |
(ii) EIN |
(iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) |
(iv) Is the organization in col. (i) listed in your governing document? |
(v) Did you notify the organization in col. (i) of your support? |
(vi) Is the organization in col. (i) organized in the U.S.? |
(vii) Amount of support? |
|||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | ||||
| Total | |||||||||
| Calendar year(or fiscal year beginning in) | (a) 2007 | (b) 2008 | (c) 2009 | (d) 2010 | (e) 2011 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | 30,491,706 | 20,760,601 | 22,553,697 | 22,876,129 | 33,247,849 | 129,929,982 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3.. | 30,491,706 | 20,760,601 | 22,553,697 | 22,876,129 | 33,247,849 | 129,929,982 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 5,362,542 | |||||
| 6 | Public Support. Subtract line 5 from line 4. | 124,567,440 | |||||
| Calendar year(or fiscal year beginning in) | (a) 2007 | (b) 2008 | (c) 2009 | (d) 2010 | (e) 2011 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 30,491,706 | 20,760,601 | 22,553,697 | 22,876,129 | 33,247,849 | 129,929,982 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 842,799 | 643,473 | 668,573 | 951,963 | 897,974 | 4,004,782 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. (Explain in Part IV.) Do not include gain or loss from the sale of capital assets.. | 4,177,745 | 155,966 | 2,756,152 | 1,735,330 | 1,624,966 | 10,450,159 |
| 11 | Total support (Add lines 7 through 10). | 144,384,923 | |||||






| Calendar year(or fiscal year beginning in) | (a) 2007 | (b) 2008 | (c) 2009 | (d) 2010 | (e) 2011 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public Support (Subtract line 7c from line 6.) | ||||||
| Calendar year (or fiscal year beginning in) | (a) 2007 | (b) 2008 | (c) 2009 | (d) 2010 | (e) 2011 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) | ||||||
| 13 | Total support (Add lines 9, 10c, 11 and 12.). | ||||||




| Facts And Circumstances Test |
|---|
| Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.| Identifier | Return Reference | Explanation |
|---|---|---|
| Program Service Accomplishments (1) | Part III, Line 4a-4d (1) | Line 4a: Research: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research. New Grants and Fellowships Grants and fellowships are awarded through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee. Guided by its scientific advisors and with the approval of its board of trustees, amfAR pursues a strategic research plan that focuses on the treatment, prevention, and cure of HIV/AIDS. In 2012, amfAR awarded more than $5 million in grants and fellowships to support 34 research projects. Five researchers received Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results, including numerous published studies in major scientific journals. The 2012 Krim Fellows-each of whom received between $80,000 and $125,000-are working on new ways to treat HIV/AIDS and its associated conditions, as well as an HIV vaccine. Among the 2012 fellows is Mattias Forsell, Ph.D., of the Karolinska Institute in Stockholm, Sweden, who is aiming to make progress towards the design of a vaccine against HIV infection. Despite a concerted effort to design an AIDS vaccine, several characteristics of the virus, such as its ability to present "decoys" to guide the immune system away from making the most effective immune responses, have made the task impossible so far. Dr. Forsell plans to elucidate the mechanisms whereby the immune cells that make antibodies generate responses to different regions of the virus, and how these cells might ultimately be guided towards making antibodies against the most vulnerable regions of the virus. Cure-Focused Studies Placing the search for a cure for HIV/AIDS at the center of its research efforts, the Foundation launched the amfAR Research Consortium on HIV Eradication (ARCHE) in 2010. In 2012, more than $1.5 million in funding went to seven collaborative teams of researchers working in three areas considered central to HIV eradication: the search for a sterilizing cure to eliminate HIV from the body; the search for a functional cure to suppress the virus without treatment; and the characterization of viral reservoirs, which present an obstacle to a cure. A series of studies by Dr. Sarah Palmer of the Swedish Institute for Infectious Disease Control and Karolinska Institute is building on an intriguing finding made during year two of ARCHE: the discovery of identical clones of latent virus. Dr. Palmer is working with Dr. Frederick Hecht of the University of California at San Francisco to understand how such clones might arise and what they mean for efforts to rid the body of the virus. Dr. Daniel Douek of the National Institutes of Health is also applying his expertise on T cells to help explain the findings. One of the principal strategies being investigated in the search for a cure involves using drugs that can activate HIV out of a latent state, allowing it to be targeted by antiretroviral therapy (ART). Working at Johns Hopkins University, Dr. Robert Siliciano's previous ARCHE research has identified agents-notably, a drug called disulfiram-that might achieve such reactivation. Dr. Siliciano aims to determine whether all of the latent virus can be reactivated. If some virus remains dormant, he will attempt to understand the mechanisms whereby it remains latent despite interactions with drugs that are intended to reverse that latency. Understanding the ability of the virus to remain stubbornly latent will have important ramifications for the design of HIV cure strategies. |
| Program Service Accomplishments (2) | Part III, Line 4a-4d (2) | LINE 4a, continued: Dr. Timothy Henrich of Harvard is studying two HIV-positive individuals who had been on long-term ART when they developed lymphomas. To treat these cancers, both underwent typical stem-cell transplants from normal donors, who had been selected only for the usual tissue-type match. Dr. Henrich found that not only were these individuals cured of their cancer, but he could find no evidence of HIV. This was true despite the fact that-unlike "The Berlin Patient," who was cured of HIV following transplant with cells from a donor selected for the CCR5 delta32 mutation, and thus resistant to HIV infection-no extraordinary measures were used here. For the moment, these two individuals remain on ART. But with amfAR funding, Dr. Henrich is interrupting their ART in a search for HIV in their blood and other tissues. Current antiretroviral therapy can in many cases reduce levels of HIV to such an extent that sensitive equipment is required to detect it, but the virus can almost always be found. Demonstrating with confidence that a cure has been achieved will require highly sensitive methods of detecting HIV at substantially lower levels than is currently possible. ARCHE grantee Dr. David Margolis of the University of North Carolina is developing just such an ultra-sensitive methodology that could be used in the test tube as well as in subjects participating in clinical trials. Published Research Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, at least 40 scientific publications resulted from amfAR-funded research. Defining HIV Reservoirs Drs. Sara Palmer and Frederick Hecht (see above) collaborated with colleagues to examine eight HIV-positive individuals and published their findings in the July issue of the Journal of Infectious Diseases. Five of the patients had started ART either during acute infection or early thereafter. Three elected to wait until at least one year following initial infection. All had received ART for at least three years at the time of study. Stem cells were extracted from bone marrow samples using a marker protein known as CD34. The DNA form of HIV was searched for in these cells by an ultra-sensitive assay Dr. Palmer developed years ago, also with amfAR funding. Results with these stem cells were compared to studies of CD4+ T cells obtained from the bone marrow and blood of the same eight subjects. Drs. Palmer and Hecht found that, "a larger pool of HIV-1-infected CD4+ T cells had been established in patients during chronic infection." This is a point critical to the argument that ART should be started as early as possible after identifying an HIV infection. Leading the Charge in Cure Research In the March issue of the journal Cell Stem Cell, three current and former ARCHE grantees, Dr. Keith Jerome of the Fred Hutchinson Cancer Research Center in Seattle and Drs. Steven Deeks and Joseph McCune of the University of California, San Francisco-who met and first discussed the idea for their paper at a stem cell think tank organized by amfAR in September 2011-suggested that one might be able to create an HIV-resistant immune system in an infected person by genetically engineering a person's own stem cells. The authors admit that such "gene modification of stem cells will be an expensive intervention" but suggest that "it may prove to be cost-effective given that decades-long administration of antiretroviral therapy would cost several hundred thousand dollars per person." "Shock and Kill" Strategy Holds Promise in the Search for a Cure Working on the "shock and kill" approach, another ARCHE member, Dr. Siliciano (see above), described his newest findings in the March issue of the Journal of Antimicrobial Chemotherapy. The "shock and kill" approach involves awakening latent virus and then killing it with ARVs, enhanced immune attack, or a combination of these methods. Using a model for latently infected T cells that they developed, Dr. Siliciano and colleagues tested a large number of chemical compounds to see which, if any, might activate growth of HIV without causing harm. They discovered two types of chemicals that not only could awaken HIV but did so without broadly stimulating the cells to produce potentially harmful immune hormones (cytokines). Supporting the possibility of turning such chemicals into useful drugs was the fact that they had characteristics of known drugs that are readily absorbed by the body and taken up by cells. New Targeted RFP amfAR issued a request for proposals (RFP) in September 2012 for biomedical research projects relevant to exploring the mechanisms for HIV persistence and the potential for HIV eradication. Think Tanks, Symposia, and Conferences An amfAR symposium in November 2011 brought together leading scientists, advocates, journalists, and one extraordinary "patient" to discuss the holy grail of AIDS research: a cure. The symposium, titled "Making AIDS History: Closing in on a Cure," featured a conversation between Timothy Brown, "The Berlin Patient," the first adult to be cured of HIV, George Stephanopoulos of ABC News, and Jeffrey Laurence, M.D., senior scientific consultant for programs at amfAR. In June 2012, a think tank organized by amfAR in San Francisco brought together 12 scientists involved in various aspects of HIV cure research, along with two bioethicists, to explore the potential for an HIV cure in infants and children. As a result of the think tank, in September amfAR awarded a grant to Dr. Deborah Persaud of Johns Hopkins Children's Center and Dr. Katherine Luzuriaga of the University of Massachusetts Medical School, enabling them to establish a research collaboratory to explore and document possible pediatric HIV cure cases. The first case of a child cured of HIV was confirmed by researchers in the collaboratory and announced by Dr. Persaud in March 2013. amfAR also played a prominent role in research-focused programming at the XIX International AIDS Conference. Vice President and Director of Research Dr. Rowena Johnston participated in a two-day pre-conference cure symposium-titled "Towards and HIV Cure"-co-chaired by Nobel prize-winning scientist Dr. Franoise Barr-Sinoussi and Dr. Steven Deeks. Dr. Johnston also co-chaired a conference session titled "Gender and Science: Shifting the Paradigm in HIV Research." |
| Program Service Accomplishments (3) | Part III, Line 4a-4d (3) | Line 4b: TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 22 adult and 21 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia HIV Observational Database (TAHOD) TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from more than 8,385 patients at 22 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. In early 2012, the TAHOD network began recruiting participants for a regional study of HIV-tuberculosis co-infection-related to socio-economic determinants of tuberculosis and adverse treatment outcomes, tuberculosis-associated immune reconstitution inflammatory syndrome, and multi-drug resistant tuberculosis. The study protocol and related materials were developed under the leadership of TREAT Asia. TREAT Asia Pediatric Network Representing more than 5,000 HIV-positive children in Asia, TREAT Asia's Pediatric Network includes 21 sites in seven countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database (TApHOD) was modeled on the adult database, and includes data from approximately 4,400 pediatric patients at 16 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. International AIDS Database TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. Adolescent Research In 2012, TREAT Asia completed two studies that it hopes will inform and improve adolescent HIV treatment and care in Southeast Asia. This first study examined the incidence of human papillomavirus (HPV) infection-a precursor to cervical and anal cancer-in HIV-positive adolescents. A second study assessed bone mineral density levels in children living with HIV and found preliminary correlations between the use of antiretroviral therapy and bone density loss. In addition, an ongoing study is using an audio-computer-assisted survey instrument (ACASI) to better understand how adolescents experience living with HIV by allowing them to anonymously respond to questions using a computer interface. Reaching Out to MSM Three workshops on the "test and treat" approach for preventing HIV transmission and increasing uptake of HIV testing and treatment services among men who have sex with men (MSM) and transgender women (TG) were held in Thailand in 2012. The workshops were held parallel with a pilot study providing ART to MSM with newly diagnosed HIV, led by the Thai Red Cross AIDS Research Centre. Exploring Links Between HIV and Cancer Among HIV-positive MSM, the risk of anal cancer is twice the level of those who are HIV-negative, but little research has been done on this issue in Asia. With funding from IeDEA, in 2009 TREAT Asia began supporting an innovative research study exploring the links between HIV and anal cancer and looking at cancer biomarkers in an attempt to better identify MSM with pre-cancerous anal lesions. Research on HPV and anal cancer risk among MSM is ongoing in the three original sites in Bangkok, Bali, and Jakarta. Building Research Capacity TREAT Asia has implemented a research education program to help network members strengthen their skills in conducting clinical research and to boost the overall quality of care in the region. TREAT Asia organized eight workshops and training sessions in 2012, including sessions on HIV testing and counseling skills, basic research skills (e.g., manuscript development and scientific writing), and clinical management of HIV. Building Community Treatment Literacy and Promoting Advocacy for Treatment Access Communicating treatment information about a disease as complex as HIV/AIDS can be daunting, but patients' lives depend on it. TREAT Asia works closely with regional organizations to support treatment literacy activities, including the production of "community-friendly" educational brochures on HIV treatment standards in local languages. In 2012, TREAT Asia funded the development of an HIV disclosure book for children and caregivers in collaboration with the South East Asia Research Collaboration with Hawaii (SEARCH) at the Thai Red Cross AIDS Research Centre. The book provides basic information on HIV for children who have recently been told about their HIV diagnosis. The language and illustrations are targeted for younger children in order to help them better understand the implications of having HIV infection. TREAT Asia continued to publish lay-language articles about new research in the fields of prevention, treatment, and basic science. The goal of these articles is to explain HIV/AIDS research advances for people living with HIV/AIDS and their families, communities, and caregivers across Asia. The articles appear in the TREAT Asia Report and on TREAT Asia's website, www.treatasia.org. XIX International AIDS Conference TREAT Asia was well represented at the conference in July 2012 in Washington, D.C. In addition to activities during the main conference, TREAT Asia staff and network investigators participated in pre-conference workshops on HIV pediatric and cure research. Two studies on risk behaviors and treatment outcomes of adolescents from TREAT Asia's pediatric HIV network were presented. 15th Bangkok Symposium on HIV Medicine amfAR continued its support of this annual regional symposium, which was held in January 2012. Dr. Annette Sohn, vice president and director of the TREAT Asia program, spoke about the use of pre-exposure antiretroviral prophylaxis in MSM. 15th International Congress on Infectious Diseases (ICID) TREAT Asia network investigators presented four studies on HIV-infected adolescents at this annual congress, which was held in June 2012 in Bangkok. |
| Program Service Accomplishments (4) | Part III, Line 4a-4d (4) | Line 4c: EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. Educational Materials amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 40,000 people; the TREAT Asia Report, published and distributed three times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to more than 40,000 people. The Foundation's newly redesigned website features news, interviews, and original articles covering science, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policy makers, healthcare professionals, people living with HIV/AIDS, and the general public. Together to End AIDS amfAR and GBCHealth honored Bill Gates at a benefit event in Washington, D.C., on the eve of the International AIDS Conference, paying tribute to the spirit of global collaboration that has underpinned the world's progress in the fight against AIDS. The event, titled "Together to End AIDS," was attended by Sharon Stone, Anderson Cooper, Jessye Norman, John Corbett, Eve, M?A?C AIDS Fund Chairman John Demsey, The Honorable Nancy Pelosi, UNAIDS Executive Director Michel Sidib, The Honorable Barbara Lee, The Honorable Ed Markey, and Health and Human Services Secretary Kathleen Sebelius, among many others. Gates received amfAR's Award of Courage for his visionary leadership on global health and HIV/AIDS. The evening kicked off the first International AIDS Conference to be held in the U.S. in more than two decades. Social Media amfAR vigorously expanded its presence in the social media arena, reaching large numbers of a people and a generally younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly added content to its Facebook page, mounted a campaign to increase Facebook followers, and live tweeted from fundraising and program events. amfAR passed 40,000 likes on Facebook in 2012 and now has more than 15,000 Twitter followers. Media Outreach amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS press coverage. Articles and reports involving amfAR-many of which included interviews with amfAR spokespeople-were carried in numerous media outlets, including The New York Times, The Wall Street Journal, The Washington Post, the Associated Press, Reuters, Bloomberg News, and The Huffington Post. amfAR's leadership role in AIDS research was highlighted in late July, during and around the International AIDS Conference in Washington, D.C., when major outlets-including The Wall Street Journal, the Associated Press, Bloomberg, and Reuters-sought commentary from amfAR's leadership. amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Fundraising Chairman Sharon Stone. In 2012, celebrity supporters included amfAR ambassadors Cheyenne Jackson, Janet Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Sarah Jessica Parker, Heidi Klum, Alan Cumming, John Benjamin Hickey, Janelle Mone, Jennifer Hudson, Elizabeth Hurley, Debbie Harry, Diane Kruger, Kylie Minogue, fun., Jessie J, Theophilus London, Chris Tucker, Adrien Brody, Dita Von Teese, Stanley Tucci, Chelsea Handler, and Katy Perry, among many others. |
| Program Service Accomplishments (5) | Part III, Line 4a-4d (5) | THE GMT INITIATIVE (formerly MSM Initiative): Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) throughout the developing world through its MSM Initiative. The program was recently renamed The GMT Initiative to better reflect the diversity of the people it serves. Through small, targeted grants to grassroots groups, amfAR helps expand access to HIV education and prevention services; supports advocacy aimed at increasing funding for prevention and treatment services; and works to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS. Community Awards In 2012, amfAR awarded more than $650,000 to 39 groups in Africa, Asia and the Pacific, the Caribbean, Eastern Europe and Central Asia, and Latin America for a wide range of projects addressing HIV prevention, outreach, education, advocacy, testing, research, and capacity building. Sample funded projects include: Africa Espoir Vie Togo (EVT) (Lom, Togo) EVT is helping to create the first ever safe space for LGBT people and other MSM in Togo. Ahoefa-The House of Peace-provides access to psychosocial support, HIV testing and counseling, prevention discussion groups, condoms, and lubricant. The group is also providing financial support for scholarships for deserving students, micro-credit programs, and vocational skills training. EVT is engaging policy makers, media representatives, religious leaders, and health care workers in discussions about stigma and homophobia and their effects on HIV vulnerability among MSM. Asia-Pacific The Human Rights Education Institute of Burma (HREIB) (Chiang Mai/Ranong, Thailand) This direct service project is supporting peer educators who teach sexual health-related knowledge and risk-reduction skills, increasing access to healthcare and vocational training, and promoting basic human rights among Burmese migrant MSM and transgender persons living in Ranong, Thailand. Caribbean Grupo Este Amor (La Romana, Dominican Republic) This transgender-specific project is helping transgender women achieve economic independence by providing HIV prevention education and small business skills. Grupo Este Amor is training transgender stylists who double as health agents to their clients, providing HIV prevention information and condoms, and encouraging HIV testing and referrals. Eastern Europe and Central Asia Penitentiary Initiative (Nikolaev, Ukraine) Based on multiple previous amfAR awards, the group advocates on behalf of, and provides services for, "outcast" GMT in prison settings, including psychological support groups and individual counseling. The organization, which received its fourth grant from amfAR, is also piloting new strategies (such as rapid HIV testing) in three prisons, as well as continuing to hold training seminars with Ministry of Justice officials on both medical and non-medical aspects of living with HIV. Latin America Fundacin Llanto, Valor y Esfuerzo (LLAVES) (San Pedro Sula, Honduras) LLAVES is training key transgender leaders to become educated in policy, law, and human rights in order to amend the Honduran Special Law on HIV to include protection for all citizens regardless of sexual orientation and gender identity. Additionally, LLAVES is working with local media to increase awareness of issues such as HIV, human rights, and sexual diversity. "In Action" Awards The GMT Initiative also made five awards as part of its Advocacy in Action program, which supports GMT-led community-based organizations that wish to influence the policies of governments and external donors. Six additional awards were made under its Evidence in Action program, which documents and evaluates the impact of community-based programs with the ultimate goal of implementing the most workable strategies for stopping the spread of HIV/AIDS. Evidence in Action was developed with support from ViiV Healthcare's Positive Action Program and the Elton John AIDS Foundation. Awards for these two programs in 2012 totaled more than $180,000. Publications As part of its efforts to raise awareness among governments, donors, and international nongovernmental organizations of the spread of HIV among GMT and to advocate effective strategies for addressing it, amfAR publishes reports on HIV and GMT. In November 2011, amfAR published a Fundraising Toolkit for GMT-led advocacy in low- and middle-income countries, offering general tips on fundraising and information about who is funding GMT groups. The toolkit is available in English, Russian, and Spanish. And with the Johns Hopkins Bloomberg School of Public Health, amfAR published Achieving an AIDS-Free Generation for Gay Men and Other MSM, a new report providing the most comprehensive analysis to date of HIV-related funding and programming for this population. XIX International AIDS Conference Led by Director Kent Klindera, the GMT Initiative was well represented at the XIX International AIDS Conference, with several community partners presenting data from amfAR-supported projects. Highlights included a presentation on sustainable funding during a Global Forum on MSM and HIV pre-conference meeting, and a skills-building session on community engagement in GMT-related research. |
| Program Service Accomplishments (6) | Part III, Line 4a-4d (6) | public policy: Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research; implement the new National HIV/AIDS Strategy; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS. Capitol Hill Briefings PEPFAR and Combination Prevention for an AIDS-Free Generation February 1, 2012 amfAR co-hosted a briefing-with the IDSA Center for Global Health Policy and the President's Emergency Plan for AIDS Relief (PEPFAR)-to discuss combination prevention approaches to HIV. Speakers were U.S. Global AIDS Coordinator Dr. Eric Goosby, Dr. Diane Havlir of the University of California, San Francisco, Dr. Chris Beyrer of the Johns Hopkins Center for Public Health and Human Rights, Dr. RJ Simonds of the Elizabeth Glaser Pediatric AIDS Foundation, and Dr. Renee Ridzon of the Bill & Melinda Gates Foundation. Beginning to End the AIDS Epidemic: What's the Research Agenda? May 23, 2012 Panelists reviewed and discussed current and upcoming areas of HIV-related research, including microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention, vaccines, and the search for a cure. Speakers included Dr. Carl Dieffenbach of the National Institute of Allergy and Infectious Diseases, Dzon Dixon Diallo of SisterLove, Inc. and Morehouse School of Medicine; and Dr. Jared Baeten of the University of Washington. A Cure for HIV/AIDS: Recent Breakthroughs and New Research Frontiers June 20, 2012 In addition to two panels of top HIV/AIDS researchers and advocates, the briefing included an interview by Judy Woodruff, co-anchor and senior correspondent of PBS News Hour, with Timothy Brown, "The Berlin Patient," the first person known to be cured of HIV. During the first panel, amfAR grantee Dr. Robert Siliciano of Johns Hopkins University School of Medicine, described his work studying ways to force latent HIV that is lying dormant in cells to become active so that it can be targeted by antiretroviral therapy. The second panel featured amfAR Trustee Regan Hofmann, former editor of POZ magazine, who urged policymakers to seize on recent scientific advances now. Harm Reduction As one of the earliest supporters of comprehensive harm reduction programs for injection drug users (IDUs), including syringe exchange, amfAR has played a leading role in advocating the implementation of these lifesaving HIV prevention programs. Immediately prior to the opening of the 2012 International AIDS Conference, amfAR and the International AIDS Society - with financial and planning support from the Open Society Foundations - convened a day-long meeting to review available evidence on effective strategies to combat HIV among people who use drugs. The meeting attracted approximately 200 participants from 30 countries, including researchers, clinicians, government officials, community-based organizations, AIDS advocates, people who use drugs, and people living with HIV. amfAR funds the only annual national survey of U.S. SEPs, which is traditionally published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report (MMWR). Under contract with the New York State Department of Health's AIDS Institute, amfAR continued to administer the distribution of harm reduction supplies to the 21 authorized SEPs statewide, which have served more than 160,000 registered participants. Shaping the Domestic Response to HIV/AIDS amfAR has long advocated the implementation of a comprehensive national HIV/AIDS strategy to address the epidemic in the U.S., where more than one million people are living with the virus. In March, amfAR spearheaded a successful consultation on the research agenda for use of modeling in addressing the domestic epidemic. More than 30 planners, AIDS directors, advocates, and modelers attended. Public policy staff members met with the new Office of National AIDS Policy (ONAP) Director Grant Colfax to discuss priorities, and set up and attended meetings on domestic appropriations with key Congressional staff. Global Health At the International AIDS Conference, amfAR released an "Action Agenda to End AIDS," developed with AVAC to identify five major short-term priorities for global AIDS programs together with realistic, annual targets through 2015. The report was the focus of a satellite session at the conference titled "Getting Real About Getting to the End of AIDS." A panel discussion moderated by renowned journalist Charlayne Hunter-Gault included Anthony Fauci, M.D., of the National Institute of Allergy and Infectious Diseases; Mike Cohen, M.D., of the University of North Carolina; Helen Rees, M.D., of the Wits Reproductive Health and HIV Institute in South Africa; Chris Collins, amfAR vice president and director of public policy; Mitchell Warren, executive director of AVAC; and other leading AIDS experts. GMT GMT-gay men, other men who have sex with men, and transgender individuals-remain one of the hardest hit and most underserved populations in the global HIV/AIDS epidemic. amfAR's policy office works closely with the Foundation's GMT Initiative (formerly MSM Initiative) to advocate expanded access to HIV prevention and treatment services for GMT worldwide, and to fight the stigma and discrimination that make GMT more vulnerable to HIV infection and inhibit equal access to care. In January, amfAR released a new report-titled "Achieving an AIDS-Free Generation for Gay Men and Other MSM"-on global funding and policy related to tackling the HIV epidemic among gay men and other MSM. The report provides the most comprehensive analysis to date of HIV-related funding and programming for this population. Focusing on eight countries, it finds that national governments have failed to adequately address the epidemic among MSM, particularly in countries that criminalize same-sex sexual behavior. At the International AIDS Conference, amfAR played a key role in a symposium session titled "Men Who Have Sex with Men and HIV"-hosted by The Lancet, whose July 28, 2012, issue featured a series on the same theme, including two articles co-authored by amfAR Vice President and Director of Public Policy Chris Collins. Collins presented one of the articles, "A call to action for comprehensive HIV services for men who have sex with men." An issue brief released by amfAR and Trust for America's Health (TFAH) in September-Ending the HIV Epidemic Among Gay Men in the United States-argues that more frequent HIV testing and linkage to appropriate care, in combination with traditional prevention measures such as consistent use of condoms and safer sex practices, are needed to bring down HIV incidence among gay men. It called for systematic changes to reduce barriers to HIV testing and treatment for gay men, including expanded provider education and training, insurance coverage, and utilization of new testing technologies. The report also urged LGBT community organizations to rededicate themselves to fighting AIDS in America. Pre-Exposure Prophylaxis (PrEP) As part of a coalition of AIDS advocacy organizations, amfAR called on the U.S. Food and Drug Administration (FDA) early in 2012 to approve the antiretroviral drug Truvada as pre-exposure prophylaxis (PrEP), and, in testimony before the advisory panel, emphasized the need for demonstration projects to determine how PrEP can be used for optimal public health impact. In July, amfAR applauded the FDA's decision to approve use of Truvada as an option for HIV prevention. The decision followed a May 10 recommendation by an advisory panel to the agency, which said that Truvada, currently approved for HIV treatment, is also a safe and effective means to prevent infection in sexually active adults. The drug, manufactured by Gilead Sciences Inc., was studied in several major trials that demonstrated the once-daily pill, when taken consistently, significantly reduces the chances of acquiring HIV. amfAR continues to advise the U.S. Government on how to incorporate Truvada into global prevention strategies and goals. |
| Policies | Form 990, Part VI, Section B | Line 11 - The Form 990 was prepared by a nationally renowned accounting firm in conjunction with the organization's financial department. A copy of the draft Form 990 was circulated to the full Board of Trustees for discussion and comment. Each Board Member was provided ample opportunity to comment on the information contained in the 990 prior to its filing with the Internal Revenue Service. Line 12 - Each officer, director, trustee and key employee of amFar ("foundation") is required to annually disclose any conflicts of interest that arise by virtue of employment, board service, or position with the foundation. The foundation monitors compliance with its conflict of interest policy through an annual questionnaire/disclosure statement that is distributed to these individuals. Potential conflicts are investigated immediately. LINE 15 - AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. |
| Disclosure | Form 990, Part VI, Section C | LIne 19 - amfar makes its Form 990 available to the public by retaining a copy at its place of business and on its website, www.amfar.org. The Form 990 is likewise published on the internet at www.guidestar.org. The Foundation's financial statements are made available in its annual report and on its website. The Foundation's governing documents and conflict of interest policy are not ordinarily made available to the public, but, if requested, will be provided at management's discretion. |
| Functional Expenses | Part IX, Lines 1 & 3 | The Foundation for AIDS Research reports its grants net of grant returns or recoveries. Periodically, grants remitted to charitable organizations are returned to AMFAR for a variety of reason. On Schedules F & I, grants are reported irrespective of whether they were ultimately returned to AMFAR since categorizing the "returned" amounts would be time consuming. Therefore, amounts reported on Part IX, Line 1 may not necessarily tie to total grants on Schedule I; amounts reported on Part IX, Line 3 may not necessarily tie to total grants on Schedule F. |
| Other Changes in Net Assets | FORM 990, SECTION XI, LINE 5 | unrealized gain..............$836,699 gain on third party trust.... (14,185) ---------- ($822,514) ========== |
| Software ID: | |
| Software Version: |